CDHR3

Across TCGA pan-cancer cohorts, CDHR3 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of CDHR3’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where CDHR3 RNA is repressed in tumor relative to normal tissue. In most cancer types CDHR3 is over-expressed in tumor, although a few such as THCA and LUAD show the opposite, repressed pattern.

THCA, KIRC, and LUAD are the cancer types where CDHR3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDHR3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	−1.408	<.001	11	view →
KIRC	Male	II,III,IV	+0.985	<.001	11	view →
LUAD	Male	II,III,IV	−2.124	<.001	9	view →
KICH	Female	All	−0.899	<.001	9	view →
LIHC	Male	All	+0.626	<.001	9	view →
LUSC	Female	All	−2.406	<.001	8	view →
BLCA	All	IV	−0.661	<.001	6	view →
READ	All	III,IV	−0.890	.017	4	view →
UCEC	All	All	−1.379	.023	2	view →
BRCA	All	II,III,IV	−0.300	.029	2	view →
HNSC	Male	III,IV	+0.533	.012	1	view →
KIRP	All	All	+0.330	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

CDHR3–THCA

Open the THCA breakdown →